Close Menu

Synthetic Biology

The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.

The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.

The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.

On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.

A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.